SANTA CLARA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2024 after market close on Monday, August 5, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. SI-BONE (NASDAQ: SIBN)is a global leader in technology for surgical treatment of muscu ...

SANTA CLARA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2024 Truist Securities MedTech Conference in Boston. Management will be hosting a fireside chat on Tuesday, June 18, at 3:40 p.m. Eastern Time / 12:40 p.m. Pacific Time. iFuse Bedrock Granite, iFuse-TORQ, SI-BONE and iFuse INTRA are registered trademarks o ...

SANTA CLARA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2024 Truist Securities MedTech Conference in Boston. Management will be hosting a fireside chat on Tuesday, June 18, at 3:40 p.m. Eastern Time / 12:40 p.m. Pacific Time. Investors interested in listening to the conference call may do so by registering at t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-38701 SI-BONE, INC. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction o ...

Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the First Quarter 2024 Annual guidance increased to $164 million - $166 million, implying annual growth of ~18% - 20% SANTA CLARA, Calif. May 6, 2024 - SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2024. First Quarter 2024 Financial Highlights (all comparisons are to the prior year period) Recent Operation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38701 SI-BONE, Inc. (Exact name of Registrant as specified in its Charter) (State or other jurisdiction of incorporation or organizat ...

SI-BONE, Inc. (NASDAQ:SIBN) Q4 2023 Earnings Call Transcript February 26, 2024 4:30 PM ET Company Participants Saqib Iqbal - Senior Director of IR Laura Francis - CEO Anshul Maheshwari - CFO Conference Call Participants Craig Bijou - Bank of America Drew Ranieri - Morgan Stanley David Saxon - Needham & Company Sam Brodovsky - Truist Securities Caitlin Cronin - Canaccord Genuity Ross Osborn - Cantor Fitzgerald Operator Good afternoon and welcome to SI-BONE's Fourth Quarter 2023 Earnings Conference Call. At t ...

Financial Performance - Revenue for Q3 2023 was $34.014 million, a 28.8% increase from $26.432 million in Q3 2022[18] - Gross profit for Q3 2023 was $26.973 million, compared to $22.264 million in Q3 2022, reflecting a gross margin improvement[18] - Net loss for Q3 2023 was $10.022 million, an improvement from a net loss of $14.158 million in Q3 2022[18] - Net loss for the nine months ended September 30, 2023, was $32.353 million, a decrease from $50.081 million in the same period of 2022, representing a 35.3% improvement[25] - For the three months ended September 30, 2023, the net loss was $10,022,000, compared to a net loss of $14,158,000 for the same period in 2022, representing a 29.8% improvement[78] - The net loss per share, basic and diluted, improved to $0.25 in Q3 2023 from $0.41 in Q3 2022, indicating a 39.0% reduction in loss per share[78] Assets and Equity - Total current assets increased to $211.019 million as of September 30, 2023, up from $137.611 million at the end of 2022[16] - Total stockholders' equity rose to $173.600 million as of September 30, 2023, compared to $98.302 million at the end of 2022[16] - Cash and cash equivalents increased to $53.492 million as of September 30, 2023, compared to $20.717 million at the end of 2022[16] - Cash and cash equivalents at the end of the period were $53.492 million, up from $26.299 million at the end of September 2022, indicating a 103.5% increase[25] - Total stockholders' equity as of September 30, 2022, was $102.828 million, down from $134.420 million as of December 31, 2021, reflecting a decrease of 23.5%[22] Operating Expenses - Operating expenses for Q3 2023 were $38.142 million, up from $35.830 million in Q3 2022, driven by increased sales and marketing efforts[18] - Total stock-based compensation expense for the three months ended September 30, 2023, was $5,928,000, slightly up from $5,922,000 in Q3 2022[76] - Research and development expenses included $699,000 in stock-based compensation for Q3 2023, compared to $672,000 in Q3 2022, marking a 4.0% increase[76] Revenue Sources - Revenue from the United States was $32.3 million for the three months ended September 30, 2023, compared to $24.627 million in the same period of 2022, reflecting a growth of 31.3%[39] - International revenue accounted for less than 10% of total revenue, with $1.714 million for the three months ended September 30, 2023, down from $1.805 million in the same period of 2022[39] Product Development and Strategy - The company expects to continue diversifying its product mix and developing new revenue opportunities[11] - The company is focused on retaining and growing its sales team to meet product demand[11] - The company introduced new products including the iFuse Bedrock Granite in 2022, expanding its product line for minimally invasive surgical implants[27] Cash Flow and Financing - The company raised $83.671 million in net proceeds from a public offering of 3,775,000 shares at a price of $22.00 per share in May 2023[28] - The company reported a net cash used in operating activities of $16.416 million for the nine months ended September 30, 2023, an improvement from $34.880 million in the same period of 2022[25] - Future results may be impacted by macroeconomic factors, with uncertainties regarding liquidity and access to funding for capital needs[30] Marketable Securities and Debt - Total marketable securities as of September 30, 2023, amounted to $152.021 million, up from $84.575 million as of December 31, 2022[43] - As of September 30, 2023, the company's outstanding debt from the term loan was $36.0 million, an increase from $35.0 million as of December 31, 2022[60] - The effective interest rate for the First-Citizens Term Loan was 9.3% for the three months ended September 30, 2023, compared to 8.3% for the same period in 2022[64] Stock Options and Compensation - The company granted 1,204,086 RSUs with an average grant date fair value of $16.85 during the nine months ended September 30, 2023[72] - The company had outstanding stock options totaling 1,216,841 shares as of September 30, 2023, with a weighted average exercise price of $10.84[67] - The total outstanding common stock warrants decreased from 118,122 as of December 31, 2022, to 85,139 as of September 30, 2023, due to the exercise of warrants[77] - The total stock options outstanding decreased from 1,921,065 in Q3 2022 to 1,216,841 in Q3 2023, reflecting a 36.6% reduction[80] Credit Quality and Risks - The allowance for credit losses increased to $750,000 as of September 30, 2023, from $400,000 at the end of 2022, indicating a provision of $352,000 during the period[51] - The company did not recognize any credit losses related to its investments during the nine months ended September 30, 2023, indicating stable credit quality[43] - The company has not experienced any losses on its deposits of cash, cash equivalents, and marketable securities despite the closure of Silicon Valley Bank[29] - The company anticipates challenges related to supply chain management and regulatory compliance impacting future performance[14]

SI-BONE, Inc. (NASDAQ:SIBN) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Saqib Iqbal - Senior Director of IR Laura Francis - CEO Anshul Maheshwari - CFO Conference Call Participants Young Li - Jefferies Drew Ranieri - Morgan Stanley Craig Bijou - Bank of America David Saxon - Needham & Company Dave Turkaly - JMP Securities Caitlin Cronin - Canaccord Samuel Brodovsky - Truist Securities Operator Good afternoon and welcome to SI-BONE's Third Quarter Earnings Conference Cal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) (State or Other Jurisdiction of Incorporation or Organization) OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-38701 SI-BONE, INC. (Exact Name of Registrant as Specified in its Charter) 471 El Camino Real, Suite 101, Santa Clara, California 95050 (Address of principal executive offices) ( ...